Stifel Financial Corp Increases Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Stifel Financial Corp lifted its stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 1.6% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 69,134 shares of the specialty pharmaceutical company’s stock after purchasing an additional 1,093 shares during the period. Stifel Financial Corp owned approximately 0.13% of Supernus Pharmaceuticals worth $2,156,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in SUPN. Armistice Capital LLC lifted its position in shares of Supernus Pharmaceuticals by 47.6% during the 2nd quarter. Armistice Capital LLC now owns 5,272,000 shares of the specialty pharmaceutical company’s stock valued at $141,026,000 after acquiring an additional 1,700,000 shares during the period. Dimensional Fund Advisors LP raised its holdings in Supernus Pharmaceuticals by 12.1% during the second quarter. Dimensional Fund Advisors LP now owns 2,866,887 shares of the specialty pharmaceutical company’s stock worth $76,690,000 after purchasing an additional 309,966 shares during the last quarter. Stephens Investment Management Group LLC raised its holdings in Supernus Pharmaceuticals by 1.8% during the third quarter. Stephens Investment Management Group LLC now owns 1,932,209 shares of the specialty pharmaceutical company’s stock worth $60,246,000 after purchasing an additional 33,710 shares during the last quarter. Pacer Advisors Inc. grew its holdings in Supernus Pharmaceuticals by 29.9% in the third quarter. Pacer Advisors Inc. now owns 1,752,882 shares of the specialty pharmaceutical company’s stock valued at $54,655,000 after purchasing an additional 403,028 shares during the last quarter. Finally, Renaissance Technologies LLC increased its position in shares of Supernus Pharmaceuticals by 26.4% in the second quarter. Renaissance Technologies LLC now owns 1,685,122 shares of the specialty pharmaceutical company’s stock valued at $45,077,000 after buying an additional 351,900 shares in the last quarter.

Insider Buying and Selling

In other news, CEO Jack A. Khattar sold 125,000 shares of the company’s stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $36.68, for a total transaction of $4,585,000.00. Following the completion of the transaction, the chief executive officer now owns 926,172 shares of the company’s stock, valued at $33,971,988.96. This represents a 11.89 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP Frank Mottola sold 15,000 shares of the stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $36.98, for a total transaction of $554,700.00. Following the transaction, the senior vice president now owns 8,200 shares in the company, valued at approximately $303,236. The trade was a 64.66 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 154,213 shares of company stock worth $5,660,180. 9.30% of the stock is owned by insiders.

Supernus Pharmaceuticals Stock Up 0.9 %

NASDAQ SUPN opened at $35.77 on Friday. Supernus Pharmaceuticals, Inc. has a fifty-two week low of $25.53 and a fifty-two week high of $39.37. The business has a fifty day moving average of $35.61 and a 200-day moving average of $32.16. The stock has a market cap of $1.98 billion, a price-to-earnings ratio of 33.43 and a beta of 0.90.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its earnings results on Monday, November 4th. The specialty pharmaceutical company reported $0.69 earnings per share for the quarter, beating the consensus estimate of $0.44 by $0.25. The firm had revenue of $175.70 million during the quarter, compared to the consensus estimate of $157.35 million. Supernus Pharmaceuticals had a net margin of 9.16% and a return on equity of 7.79%. The firm’s revenue for the quarter was up 14.2% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.29) EPS. As a group, analysts anticipate that Supernus Pharmaceuticals, Inc. will post 2.37 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on SUPN shares. Cowen reiterated a “buy” rating on shares of Supernus Pharmaceuticals in a research report on Friday, October 18th. Piper Sandler reiterated a “neutral” rating on shares of Supernus Pharmaceuticals in a research report on Friday, October 18th.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.